HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses.

Abstract
Superinfection by hepatitis delta virus (HDV) in hepatitis B virus chronic carriers is normally associated with a progressive liver injury. For this reason, the aim of the present study was to determine the efficacy of recombinant interferon alpha (rIFN-alpha) treatment of chronic delta hepatitis, by giving high doses of rIFN-alpha 2c during a prolonged period. A total of 20 HBsAg, anti-HD carriers with a chronic active hepatitis were randomly allocated in two groups: (I) n = 10, control and (II) n = 10, treated with 10 MU/m2 body surface of rIFN-alpha, twice weekly, intramuscularly (im) during 6 months. Basally, all patients presented HDAg in the liver and serum IgM anti-HD. Serum HDV-RNA was positive in 8 and 7 patients from groups I and II, respectively. The interferon therapy was well tolerated and all patients finished the treatment period. During the first 6 months, a decrease in ALT levels among treated patients (255 +/- 98 vs. 193 +/- 117) was observed. In addition, a transient drop in HDV-RNA levels was also observed. No changes in anti-HD titer, IgM anti-HD and HBsAg concentration were detected. At the end of the follow-up period (15 months) two treated patients had lost IgM anti-HD. In addition, another two patients were HDV-RNA negative. In conclusion, no permanent antiviral effects of rIFN-alpha 2c in chronic delta hepatitis, using this schedule, was achieved.
AuthorsJ C Porres, V Carreño, J Bartolomé, A Moreno, F Galiana, J A Quiroga
JournalJournal of hepatology (J Hepatol) Vol. 9 Issue 3 Pg. 338-44 (Nov 1989) ISSN: 0168-8278 [Print] Netherlands
PMID2691569 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Interferon Type I
  • Recombinant Proteins
Topics
  • Adult
  • Biopsy
  • Carrier State
  • Female
  • Follow-Up Studies
  • Hepatitis B (complications)
  • Hepatitis D (complications, immunology, therapy)
  • Hepatitis, Chronic (therapy)
  • Humans
  • Interferon Type I (administration & dosage, adverse effects, therapeutic use)
  • Liver (pathology)
  • Liver Function Tests
  • Male
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: